[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100546204":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":32,"centralContacts":37,"locations":47,"responsibleParty":65,"collaborators":69,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":74,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":41,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":41,"overallStatus":50,"whyStopped":41,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Elisabethinen Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"ctDNA guided","EXPERIMENTAL","All patients included into the study are recommended to go for upfront surgery (localized and resectable tumor in CT and CA19-9 \\\u003C500kU\u002Fl) by tumor board.\n\nIf preoperative ctDNA in peripheral blood is positive, we assume high risk for early recurrence (because of systemic tumor burden) and apply neoadjuvant chemotherapy at physicians choice instead.",[13],"Procedure: Neoadjuvant chemotherapy instead of upfront surgery",{"label":15,"type":6,"description":16,"interventionNames":17},"Standard of care","Patient get the gold standard treatment at physicians choice, independent to study participation (here the study is just observational).",[18],"Procedure: Upfront surgery",[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"PROCEDURE","Neoadjuvant chemotherapy instead of upfront surgery","All patients included into the study are recommended to go for upfront surgery (CT and CA19-9) by tumor board.\n\nIf preoperative ctDNA is positive, the investigators assume high risk for early recurrence (because of systemic tumor burden) and apply neoadjuvant chemotherapy at physicians choice instead.\n\n* Apart from blood collection (within the scope of clinical routine), there is no additional diagnostic intervention performed on the patient.\n* The respective neoadjuvant chemotherapeutical drug will be selected and applied by the treating medical oncologist at physicians choice (unaffected by study participation), usually mFOLFIRINOX or Gemcitabine\u002FnabPaclitaxel at standardized dosage recommended by NCCN and local guidelines.\n\nFOLFIRONOX: Folinic acid (also known as leucovorin), F - Fluorouracil (5-FU), IRIN - Irinotecan, OX - Oxaliplatin.",[9],[26],"Experimental",{"type":21,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"Upfront surgery","Standard of care as recommended by tumor board (not affected by study conditions).",[15],[15],[33],{"name":34,"affiliation":35,"role":36},"Patrick Kirchweger, MD, PhD","Ordensklinikum Linz, Department of Surgery","PRINCIPAL_INVESTIGATOR",[38,43],{"name":34,"role":39,"phone":40,"phoneExt":41,"email":42},"CONTACT","+436644159646",null,"patrick.kirchweger@ordensklinikum.at",{"name":44,"role":39,"phone":45,"phoneExt":41,"email":46},"Helwig Wundsam, PD, MD","+4373276774562","helwig.wundsam@ordensklinikum.at",[48],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Ordensklinikum Linz Barmherzige Schwestern","RECRUITING","Linz","Upper Austria","4010","Austria","AT",{"type":57,"coordinates":58},"Point",[59,60],14.28611,48.30639,{"lat":60,"lon":59},[63,64],{"name":34,"role":39,"phone":40,"phoneExt":41,"email":42},{"name":44,"role":39,"phone":45,"phoneExt":41,"email":46},{"type":36,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":68,"oldNameTitle":41,"oldOrganization":41},"Patrick Kirchweger","Principal Investigator","Krankenhaus Barmherzige Schwestern Linz",[70],{"name":71,"class":6},"Medical University Innsbruck","100546204","phase-3-liquid-biopsy-ctdna-guided-treatment-in-localized-pancreatic-cancer-neoadjuvant-ctx-vs-upfront-surgery-100546204",false,"NCT06391892","Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery","Liquid Biopsy Guided Treatment in Localized Pancreatic Cancer (LIQUIPANC): Circulating Tumor DNA (ctDNA) as Precision Medicine Tool for Stratification of Neoadjuvant Chemotherapy vs. Upfront Surgery","LIQUIPANC","Inclusion Criteria:\n\n* Informed consent\n* \\>18 years old\n* localized pancreatic cancer to go for upfront surgery\n\nExclusion Criteria:\n\n* synchronous secondary malignancy\n* pregnancy","ALL","18 Years","99 Years",{"count":84,"type":85},100,"ESTIMATED","INTERVENTIONAL",[88],"PHASE3","This study evaluates the clinical prognostic impact (on DFS and OS) of liquid biopsy guided treatment vs. standard of care (physicians choice) in localized pancreatic cancer (despite because of CA 19-9 levels and computed tomography, upfront surgery is recommended by tumor board). ctDNA positive patients will receive neoadjvuant chemotherapy at current gold standard physicians choice instead of upfront surgery, because of assumed high biological risk for early recurrence.",[91,92,93],"Pancreatic Cancer","Circulating Tumor Cell","Predictive Cancer Model","2024-04-25",{"date":96,"type":97},"2024-04-30","ACTUAL",{"date":99,"type":97},"2024-01-11",{"date":101,"type":85},"2026-12-31",{"name":5,"class":6},1]